Therapeutic fasting
Reading File
Finding Sources
Searching PubMed
therapeutic fasting intermittent fasting health outcomes
Searching the Web
therapeutic fasting clinical evidence 2025 2026
Reading File
Finding Sources
Reading Article
Reading File
Reading File
Reading File
Finding Sources
Reading File
I now have enough material from authoritative textbooks and cutting-edge meta-analyses. Here is a thorough synthesis.
Therapeutic Fasting
What It Is
Therapeutic fasting is the deliberate, structured restriction of caloric intake (or total abstinence from food) for defined periods to achieve medical or health-optimization goals. It is distinct from starvation in that it is intentional, time-limited, and usually medically supervised. The umbrella term covers several distinct protocols:
| Protocol | Description |
|---|---|
| Intermittent fasting (IF) | Severe caloric restriction for 2-4 days/week; unrestricted eating on remaining days |
| Intermittent energy restriction (IER) | Planned cycles of negative energy balance within a prolonged weight-loss effort |
| Time-restricted feeding (TRF) | All calories consumed within a compressed daily window (e.g., 6-8 hrs) |
| Alternate-day fasting (ADF) | Fasting or very-low-calorie days (500-600 kcal) alternating with unrestricted days |
| Modified ADF (5:2 diet) | 5 days normal eating, 2 non-consecutive days at ~500 kcal |
| Prolonged/extended fasting | Multi-day water-only or very-low-calorie fasting under medical supervision |
| Caloric restriction (CR) | Sustained 20-40% reduction below maintenance calories, without malnutrition |
Physiological Mechanisms
Metabolic Switching
During fasting, the body depletes hepatic glycogen (within ~12-18 hours) and shifts to fat oxidation and ketogenesis. Beta-hydroxybutyrate (BHB) and acetoacetate replace glucose as the primary fuel for the brain and heart. This "metabolic switch" appears to drive many of the downstream benefits.
Nutrient-Sensing Pathways
Fasting modulates the major longevity/metabolism pathways (Harrison's, p. 3916):
- Insulin/IGF-1 signaling - reduced insulin and IGF-1 lower downstream PI3K/Akt/mTOR activity
- mTOR inhibition - reduces anabolic drive, promotes protein quality control
- AMPK activation - the cellular "low-fuel sensor," stimulates fat oxidation, mitochondrial biogenesis
- SIRT1 (sirtuin) activation - NAD+-dependent deacetylase; key mediator of caloric restriction-induced longevity effects
- FGF21 induction - a fasting hormone that coordinates metabolic adaptation
Autophagy
Autophagy (cellular self-digestion of damaged organelles and misfolded proteins) is strongly induced by fasting via mTOR inhibition. Autophagy declines with aging, and caloric restriction restores it - this is thought to be one of the primary pathways linking fasting to healthspan extension. From Harrison's (p. 3916): "Autophagy is activated by caloric restriction, spermidine, and inhibition of mTOR, all of which are associated with delayed aging."
Documented Clinical Benefits
1. Weight and Body Composition
Intermittent fasting reduces body weight and fat mass, but current evidence suggests it is not superior to continuous caloric restriction for weight loss when caloric intake is equated:
- Sleisenger & Fordtran's (p. 118): "Meta-analyses on IER conclude that it is an alternative, while not superior, approach to chronic energy restriction for inducing weight loss, although some patients may demonstrate greater adherence."
- The 2026 Cochrane systematic review (Garegnani et al., Cochrane 2026) - the most rigorous analysis to date, 22 RCTs, 1995 participants - found IF resulted in little to no difference vs. regular dietary advice in percentage weight loss (MD -0.33%, 95% CI -0.92 to 0.26; low-certainty evidence). Achieving a 5% weight loss threshold was also similar (RR 0.98).
- A 2025 BMJ network meta-analysis (Semnani-Azad et al.) confirmed this finding across IF strategies.
2. Cardiometabolic Parameters
Despite modest weight effects, fasting consistently improves metabolic markers:
- Reductions in fasting glucose and fasting insulin
- Improved insulin sensitivity / reduced insulin resistance
- Reductions in leptin; possible increases in adiponectin
- Modest improvements in LDL, triglycerides, and blood pressure in some trials
- These benefits are largely proportional to weight lost and may not exceed those of equivalent continuous restriction
3. Aging and Longevity (Experimental/Translational)
From Robbins, Cotran & Kumar (p. 302): "Caloric restriction has been convincingly demonstrated to increase lifespan in experimental animals, including monkeys."
The pathways involved:
- Reduced insulin/IGF-1 signaling increases lifespan in C. elegans, flies, and mice
- Sirtuin deacetylases (especially SIRT1, SIRT6) are key mediators; loss of Sirt6 causes premature aging in mice; CR-induced SIRT1/6 increases extend healthspan
- mTOR inhibition (via rapamycin or CR) extends lifespan in all model organisms tested
Translational evidence in humans is more limited, though CR studies (e.g., CALERIE trial) show improvements in cardiovascular risk factors and markers of biological aging.
4. Inflammation
Fasting reduces circulating inflammatory cytokines (IL-6, TNF-alpha, CRP). The mechanism likely involves both adipose tissue reduction and direct effects of ketone bodies (BHB acts as an NLRP3 inflammasome inhibitor).
5. Neurological Effects
Animal models show fasting may reduce neurodegeneration risk via autophagy induction and BDNF upregulation. Human data are limited but emerging for conditions including epilepsy (ketogenic diet) and potentially Alzheimer's disease.
6. Cancer - Adjunctive Role
Emerging evidence (primarily preclinical) suggests periodic fasting may reduce cancer risk and enhance chemotherapy efficacy via multiple mechanisms: reduced IGF-1/mTOR signaling, autophagy induction, and differential stress resistance (normal cells vs. cancer cells). A 2026 review notes fasting-mimicking diets combined with ketogenic approaches enhance AMPK activation and reduce tumor markers in early clinical studies.
Key Contraindications and Cautions
- Absolute contraindications: eating disorders, pregnancy and breastfeeding, type 1 diabetes (risk of DKA), severe underweight/malnutrition, pediatric populations
- Relative contraindications: type 2 diabetes on insulin or sulfonylureas (hypoglycemia risk - requires medication adjustment), history of hypoglycemia, active serious illness, liver/kidney disease
- All antiobesity pharmacotherapy is pregnancy category X - relevant when fasting is combined with pharmacotherapy for weight management
- The degree of restriction required for life-extension effects seen in animal models "is substantial, leading some to question whether such a prolonged life is worth living" (Robbins, Cotran & Kumar, p. 302)
Adherence and Practical Considerations
A key theoretical advantage of IF over continuous restriction is improved adherence for some patients - cycles of restriction may be psychologically easier than daily limitation. However, Sleisenger & Fordtran notes the data are "equivocal on whether IER in fact mitigates the counterregulatory mechanisms aimed at weight regain after diet-induced weight loss."
Harrison's conclusion (22nd ed., 2025): "While intriguing, it remains to be seen whether people will be willing to maintain strict intermittent fasting regimens over long periods of time or if short-term clinical benefits can be obtained in combination with other therapeutic approaches."
Recent Evidence Summary (2024-2026)
| Study | Finding |
|---|---|
| Cochrane 2026 (PMID 41692034) | IF = continuous dieting for weight loss; low-certainty evidence |
| BMJ network meta-analysis 2025 (PMID 40533200) | All IF strategies similar in cardiometabolic outcomes |
| Nutrients meta-analysis 2024 (PMID 39458528) | Fasting not superior to continuous restriction in obese adults |
| Nutr Metab Cardiovasc Dis 2025 (PMID 39732588) | Isocaloric IF not superior to standard caloric restriction |
Bottom Line
Therapeutic fasting - particularly intermittent fasting - is a safe and viable dietary approach for many adults, with genuine metabolic benefits. Its primary proven mechanism is caloric restriction. The weight loss achieved is comparable to (but not greater than) continuous caloric restriction. Its real advantages may lie in patient preference, adherence for specific individuals, and potential non-caloric mechanisms (autophagy, mTOR inhibition, metabolic switching) whose clinical relevance in humans is still being defined. The most rigorous 2026 evidence (Cochrane review) tempers earlier enthusiasm, indicating IF should be offered as one option among several rather than a uniquely superior strategy.
Sources: Harrison's Principles of Internal Medicine 22E (2025); Sleisenger & Fordtran's GI & Liver Disease; Robbins, Cotran & Kumar Pathologic Basis of Disease; Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Cochrane Database Syst Rev 2026 (PMID 41692034); BMJ 2025 (PMID 40533200)
This is a shared conversation. Sign in to Orris to start your own chat.